Compare CMTL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | ATNM |
|---|---|---|
| Founded | 1967 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 47.1M |
| IPO Year | N/A | N/A |
| Metric | CMTL | ATNM |
|---|---|---|
| Price | $3.08 | $1.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 201.8K | 163.1K |
| Earning Date | 12-11-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $494,760,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.15 | $42,943.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.19 | $1.03 |
| 52 Week High | $4.88 | $2.41 |
| Indicator | CMTL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 57.56 |
| Support Level | $2.97 | $1.37 |
| Resistance Level | $3.73 | $1.69 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 18.42 | 52.78 |
Comtech Telecommunications Corp is a provider of modern communications solution incorporated in USA. The company is engaged in designing, developing, producing and marketing products, systems, and services for communications solutions. It is engaged in two business segments, Satellite and Space Communications and Terrestrial and Wireless Networks. It's Space and satellite is USA based providers of modems and high-power amplifiers, a market leader in troposcatter technologies, and serves some of the world's defense contractors and allied foreign governments. Terrestrial and Wireless Networks segment is a provider of next generation 911 infrastructure and solutions for state and local governments and carriers. Majority of sales are generated from Satellite and Space Communications segment.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.